Evidence map›Paper›PMID 41650822›Full record

ArticleRedox biology2026

NRF2 deficit prevents pathologic Tau seeding and spreading in an induced tauopathy mouse model.

Yaiza López-Sampere, Pol Mengod Soler, Sergio Roca-Pereira, Antonia Vinyals, Xoel Mato-Blanco, Marta Vela-Martínez, Farida Dakterzada, Leila Romero, Enrique Santamaría, Joaquín Fernández-Irigoyen and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yaiza López-SampereNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Pol Mengod SolerNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Sergio Roca-PereiraNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Antonia VinyalsNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Xoel Mato-BlancoNeurogenomics Group, Hospital del Mar Research Institute, Parc de Recerca Biomèdica de Barcelona (PRBB), Dr. Aiguader, 88, Barcelona, Catalonia, 08003, Spain.
Marta Vela-MartínezNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Farida DakterzadaCognition and Behaviour Study Group - Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, 25196, Spain.
Leila RomeroCognition and Behaviour Study Group - Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, 25196, Spain.
Enrique SantamaríaProteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA)., Pamplona, Navarra, 31008, Spain.
Joaquín Fernández-IrigoyenProteomics Unit, Clinical Neuroproteomics Laboratory, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA)., Pamplona, Navarra, 31008, Spain.
Isidro FerrerDepartment of Pathology and Experimental Therapeutics - Bellvitge Faculty, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
Mónica PovedanoNeurology and Neurogenetics Group - Neuroscience Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
José Antonio Del RioNetwork Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, Barcelona, 08028, Spain; Institute of Neurosciences, University of Barcelona, Barcelona, Spain; Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, 08028, Spain.
Gabriel SantpereNeurogenomics Group, Hospital del Mar Research Institute, Parc de Recerca Biomèdica de Barcelona (PRBB), Dr. Aiguader, 88, Barcelona, Catalonia, 08003, Spain.
Manuel Portero-OtínMetabolic Pathophysiology Research Group, Department of Experimental Medicine, University of Lleida - Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, 25196, Spain.
Gerard Piñol-RipollCognition and Behaviour Study Group - Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, 25196, Spain. Electronic address: gerard_437302@hotmail.com.
Pol Andrés-BenitoNetwork Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, L'Hospitalet de Llobregat, Barcelona, 08907, Spain; Cognition and Behaviour Study Group - Institute for Research in Biomedicine of Lleida (IRBLleida), Lleida, 25196, Spain; Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Science Park of Barcelona, Barcelona, 08028, Spain. Electronic address: pol.andres.benito@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNuclear factor erythroid 2-related factor 2 (NRF2) regulates antioxidant defenses and protects against neurodegeneration, including Alzheimer's disease (AD). Its age-related decline disrupts redox balance and increases neuronal vulnerability, but the early hippocampal effects remain unclear. Here, we tested whether NRF2 loss affects tau seeding and spreading in a PHF-tau-inoculated mouse model, contributing to accelerated aging. METHODOLOGY: Three-month-old NRF2-knockout (Nfe2l2

resultsPHF-tau inoculation at 3 months of age in Nfe2l2

conclusionOur findings suggest that NRF2 loss induces a hippocampal state marked by impaired antioxidant defenses, astrocytic remodeling, and disrupted tau isoform balance. This environment, while metabolically altered, paradoxically hinders tau propagation, highlighting NRF2 as a key regulator of both redox and cellular maturity programs essential for tau spread and as a potential therapeutic target in tauopathies.

Indexed as

NF-E2-Related Factor 2Tauopathiestau ProteinsAlzheimer DiseaseAnimalsDisease Models, AnimalHippocampusHumansMiceMice, KnockoutOxidative StressProteomicsNfe2l2 protein, mouseNF-E2-Related Factor 2tau ProteinsAgingAlzheimer's diseaseNRF2Oxidative stressTau

Identifiers

PMID41650822
PMCPMC12907107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.